Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COCP Stock Forecast 2026-2027
$1.01
Current Price
$13.99M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to COCP Price Targets
+890.1%
To High Target of $10.00
+692.1%
To Median Target of $8.00
+494.1%
To Low Target of $6.00
COCP Price Momentum
-3.8%
1 Week Change
-29.9%
1 Month Change
-38.8%
1 Year Change
+3.1%
Year-to-Date Change
-62.2%
From 52W High of $2.67
+17.4%
From 52W Low of $0.86
📊 TOP ANALYST CALLS
Did COCP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cocrystal Pharma is one of their latest high-conviction picks.
Latest COCP Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, COCP has a bullish consensus with a median price target of $8.00 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.01, the median forecast implies a 692.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 494.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCP Analyst Ratings
2
Buy
0
Hold
0
Sell
COCP Price Target Range
Low
$6.00
Average
$8.00
High
$10.00
Current: $1.01
Latest COCP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 20, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| May 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 3, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 4, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 4, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 24, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 24, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 7, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 12, 2020 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $4.50 |
| Jul 8, 2020 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jun 16, 2020 | Noble Capital Markets | Outperform | Initiates | $N/A |
Cocrystal Pharma Inc. (COCP) Competitors
The following stocks are similar to Cocrystal Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
COCP
Cocrystal Pharma
mkt cap
13.30M
Cocrystal Pharma Inc. (COCP) Financial Data
Cocrystal Pharma Inc. has a market capitalization of $13.99M with a P/E ratio of -1.3x. The company generates $225,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -1,047.1% and return on equity of -154.6%.
Valuation Metrics
Market Cap
$13.99M
Enterprise Value
$10.03M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
59.1x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-1,047.1%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.7%
Current Ratio
2.7x
Debt/Equity
34.6x
ROE
-154.6%
ROA
-62.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cocrystal Pharma Inc. (COCP) Business Model
About Cocrystal Pharma Inc.
What They Do
Develops novel antiviral therapeutics for viral infections.
Business Model
Cocrystal Pharma Inc. operates as a clinical-stage biotechnology company, focusing on discovering and developing antiviral drugs. The company generates revenue through partnerships, research funding, and potential future sales of its therapeutics once they receive regulatory approval.
Additional Information
Cocrystal's key programs include CDI-988, which has received FDA Fast Track designation, and CC-42344, aimed at treating various influenza strains. The company leverages advanced technologies and expertise to address unmet medical needs in antiviral treatments, positioning itself as a significant player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
11
CEO
Dr. Sam Lee Ph.D.
Country
United States
IPO Year
2012
Website
www.cocrystalpharma.comCocrystal Pharma Inc. (COCP) Latest News & Analysis
Latest News
Quick Summary
Cocrystal Pharma Inc. has appointed James Sapirstein as CEO, effective immediately, replacing Sam Lee and Jim Martin. Lee remains President and transitions to Chief Scientific Officer.
Why It Matters
Cocrystal Pharma's leadership change signals a strategic shift that could influence company direction and investor confidence, impacting stock performance and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
13 days ago
Quick Summary
Cocrystal Pharma is developing novel antiviral treatments targeting hantavirus, bunyavirus, and influenza, addressing significant unmet medical needs with no current approved therapies.
Why It Matters
Cocrystal Pharma's development of novel antivirals for serious viral infections may position the company as a leader in a high-demand market, potentially increasing its stock value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
24 days ago
Quick Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported updates on its antiviral pipeline and business activities, along with financial results for Q1 2026, ending March 31.
Why It Matters
Cocrystal's updates on its antiviral pipeline and financial results can influence stock performance, indicating potential growth or risk that affects investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cocrystal Pharma presented its first oral protease inhibitor, CDI-988, at the ICAR 2026, highlighting its mechanism of action and Phase 1 study results for norovirus treatment.
Why It Matters
Cocrystal Pharma's presentation on CDI-988 highlights significant advancements in antiviral treatment, potentially boosting investor confidence and impacting stock performance based on market reaction to innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA granted Fast Track designation to the company, aimed at expediting the development and review of drugs for serious conditions and unmet medical needs.
Why It Matters
FDA Fast Track designation can accelerate a drug's path to market, potentially leading to faster revenue generation and a competitive edge, impacting the company's stock performance and market valuation.
Source: Benzinga
Market Sentiment:
Positive
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
2 months ago
Quick Summary
Cocrystal Pharma's CDI-988, an oral antiviral for norovirus, has received FDA Fast Track designation, accelerating its development and regulatory review. Norovirus affects 685 million globally annually.
Why It Matters
FDA Fast Track designation for Cocrystal's CDI-988 could lead to quicker market entry, potentially positioning the company favorably in a high-impact market, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About COCP Stock
What is Cocrystal Pharma Inc.'s (COCP) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Cocrystal Pharma Inc. (COCP) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.
Is COCP stock a good investment in 2026?
According to current analyst ratings, COCP has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COCP stock?
Wall Street analysts predict COCP stock could reach $8.00 in the next 12 months. This represents a 692.1% increase from the current price of $1.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cocrystal Pharma Inc.'s business model?
Cocrystal Pharma Inc. operates as a clinical-stage biotechnology company, focusing on discovering and developing antiviral drugs. The company generates revenue through partnerships, research funding, and potential future sales of its therapeutics once they receive regulatory approval.
What is the highest forecasted price for COCP Cocrystal Pharma Inc.?
The highest price target for COCP is $10.00 from at , which represents a 890.1% increase from the current price of $1.01.
What is the lowest forecasted price for COCP Cocrystal Pharma Inc.?
The lowest price target for COCP is $6.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 494.1% increase from the current price of $1.01.
What is the overall COCP consensus from analysts for Cocrystal Pharma Inc.?
The overall analyst consensus for COCP is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are COCP stock price projections?
Stock price projections, including those for Cocrystal Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:30 AM UTC